Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dulaglutide biosimilar - Shandong Boan Biotechnology

Next Previous
Drug Profile

Dulaglutide biosimilar - Shandong Boan Biotechnology

Alternative Names: BA 5101; Boyouping; LY-05008; Trulicity biosimilar - Luye Pharma Group; Trulicity® biosimilar

Latest Information Update: 15 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shandong Boan Biotechnology
  • Developer Luye Pharma Group
  • Class Antihyperglycaemics; Glucagon-like peptides; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 31 Mar 2026 Launched for Type 2 diabetes mellitus in China (SC) prior to March 2026- First global launch
  • 05 Aug 2025 Registered for Type 2 diabetes mellitus in China (SC) (Luye Pharma pipeline, March 2026).
  • 21 Jul 2025 FDA approves IND application for Dulaglutide biosimilar in Type 2 diabetes mellitus for rest of the world, prior to July 2025 (Shandong Boan Biotechnology pipeline, July 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top